Сравнительная оценка эффективности, безопасности и возможностей химиотерапии второй линии терапии метастатического рака желудка

Согласно данным опубликованных рандомизированных исследований терапии второй линии у пациентов с диагнозом «рак желудка» увеличение медианы выживаемости на фоне монотерапии химиопрепаратами (доцетакселом или иринотеканом) составляет приблизительно 1,5 месяца по сравнению с симптоматической терапиеий. Имеются данные сравнительных исследований по оценке эффективности других таргетных препаратов: применение эверолимуса в качестве препаратов второй линии не выявило значительного увеличения ОВ; исследования анти-EGFR-терапии (добавление панитумумаба или цетуксимаба к химиотерапии) в качестве терапии первой линии также не продемонстрировали значительного увеличения ОВ или ВВП соответственно. Увеличение ОВ у пациентов, получавших комбинацию рамуцирумаба и паклитаксела, по сравнению с группой плацебо и паклитаксела может быть признано клинически значимым для этой популяции пациентов и позволит рассматривать данный терапевтический режим как новый стандарт второй линии лечения у пациентов с данной нозологией

рак желудка, химиотерапия второй линии, рандомизированные исследования

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan. iarc.fr (accessed Feb 28, 2014)

2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W. Chemotherapy in advanced gastric cancer: A systematic re- view and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-09.

3. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-18.

4. Ford HER, Marshall A, Bridgewater JA, et al, on behalf of the COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase randomised controlled trial. Lancet Oncol 2014; 15: 78-86.

5. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second- line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinscha Internistische Onkologie (AIO). Eur J Cancer2011; 47:2306-14.

6. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advan- ced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.

7. Kodera Y, Ito S, Mochizuki Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Can- cer (CCOG0302 study). Anticancer Res 2007; 27 (4C): 2667-71

8. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of pac- litaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998; 9: 307-10.

9. Marcello Maugeri-Sacca, Laura Pizzuti, Domenico Sergi et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort J Exp Clin Cancer Res. 2013; 32 (1): 67.

10. Ueda S, Hironaka S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized phase III study or irinotecan (CPT-11) versus weekly paclitaxel (wPTX) fir advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 [abstract] J Clin Oncol. 2012; 30 (Suppl): 4002

11. Guimbaud R, Louvet C, Bonnetain F, Viret F, Samalin E, Gornet JM, Andrä T, Rebischung C, Bouche O, Jouve JL. Final results of the intergroup FFCDGERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers [abstract] Ann Oncol. 2010; 21 (8): viii 250.

12. Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Isikdogan A, Alkis N, Buyukberber S, Yumuk F, Budakoglu B, Demirci U, Berk V, Bilici A, Inal A, Arpaci E, Benekli M. Anatolian Society of Medical Oncology (ASMO) The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. J Chemother. 2012; 4:217-220.

13. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metas- tasis a er failure of prior combination chemotherapy using uo- ropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol2013; 31: 4438-44.

14. Ji SH, Lim do H, Yi SY, et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009; 9: 110.

15. Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-40.

16. SuzukiS, Dobashi Y, Hatakeyama Y, et al. Clinicopathological signi cance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-ß phosphorylation, and microvessel density in gastric cancer. BMC Cancer 2010; 10: 659.

17. Jung YD, Mans eld PF, Akagi M, et al. E ects of combination anti-vascular endothelial growth factor receptor and antiepider- mal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38: 1133-40.

18. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in com- bination with chemotherapy as rst-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-76.

19. Van Cutsem E, de Haas S, Kang KY, et al. Bevacizumab in combination with chemotherapy as rst-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30: 2119-27.

20. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-87.

21. Fuchs CS, Tomasek J, Yong CJ, et al, for the REGARD Trial In- vestigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarci- noma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2014; 383: 31-39.

22. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously trea- ted advanced gastric cancer: results of the randomized, doub- leblind, phase III GRANITE-1 study. J Clin Oncol 2013; 31: 3935-43.

23. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase III trial. Lancet Oncol 2013; 14:481-89.

24. Lordick F, Kang Y-K, Chung H-C, et al, on behalf of the Arbeitsgemeinscha Internistische Onkologie (AIO) and EXPAND Investigators. Capecitabine and cisplatin with or without cetu- ximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 6: 490-99.

25. Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Ja er Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D Schwartz, Atsushi Ohtsu, для исследовательской группы RAINBOW Lancet Oncol 2014; 15: 1224-35.